Watch out, AstraZeneca: UCB uncorks late-stage success for $2.1B Soliris rival
Just over two years after spending more than $2 billion to acquire the drug, UCB announced that zilucoplan proved effective at treating the rare autoimmune disease myasthenia gravis in a large Phase III trial.
Although UCB declined to share any specific numbers, the Belgian pharma said patients on the drug showed significant improvement over placebo on all primary and secondary endpoints, notably including three different scales used to track symptoms of the complex disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.